Abstract

Objective To investigate the effects of different doses of aspirin on serum C-reactive protein level in patients with coronary heart disease. Methods A total of 120 patients with coronary heart disease admitted to Chengyang People's Hospital of Qingdao from January 2017 to March 2018 were selected as observation group. All patients were randomly divided into group A, B and C, 40 cases in each group. Forty healthy persons in the same period were selected as control group. All patients in group A, B and C received oral aspirin. The dosage of aspirin was 50 mg/d in group A, 150 mg/d in group B, and 300 mg/d in group C. The duration of treatment was 1 month. Serum C-reactive protein levels in different groups before and after treatment were compared. Results The level of serum C-reactive protein in the observation group was (4.75 ±0.18) mg/L, while that in the control group was (2.82±1.09) mg/L. The level of serum C-reactive protein in the observation group was higher than that in the control group (P 0.05). There was no significant difference in serum C-reactive protein level between group A and B after treatment (P>0.05). The level of C-reactive protein in group C after treatment was lower than that before treatment (P<0.05), and lower than that after treatment in group A and B (P<0.05). Conclusion The level of serum C-reactive protein in patients with coronary heart disease is higher than that in healthy people. High dose of aspirin (300 mg/d) can effectively reduce the level of C-reactive protein. Key words: C-reactive protein; Coronary heart disease; Aspirin

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.